Teva has given up on a key trial of one of its original lineup of innovative medicines. | Teva has given up on a key trial of ...
The FDA has put a partial hold on Biosciences’ seizure study application over preclinical toxicity data and concerns about ...
Tiziana Life Sciences’ intranasal drug has hit the dual endpoints of a phase 2a study in patients with a form of multiple sclerosis (MS), although the win was slightly marred by the higher dose ...
Clinical research is advancing quickly, but scientific momentum is colliding with persistent operational constraints. | Mike Novotny examines the funding, technology and operational challenges shaping ...
The PASI 90 rate, which is in line with the phase 2 result, looks competitive. Cross-trial comparisons can be unreliable, ...
The drug programs left behind after Jazz Pharmaceuticals' $820 million acquisition of Actio Biosciences have found a new home ...
AstraZeneca has punted a pair of early-phase prostate cancer progra | AstraZeneca has punted a pair of early-phase prostate ...
Roche announced the global launch of its VENTANA BAP1 (SP527) test, an automated, ready-to-use immunohistochemistry (IHC) assay . The highly specific diagnostic tool is designed to help clinicians and ...
With the U.S. patent on the immunology megablockbuster Dupixent set to expire in 2031, time is running out for Sanofi to find ...
Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental ...
Bristol Myers Squibb has scrapped a phase 1 program it licensed from Prothena for $80 million. | Bristol Myers Squibb has ...
BioMarin is paying $70 million upfront to license a Fabry disease drug candidate, expanding the franchise it acquired through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results